MERETEK UBT KIT (W/ PRANACTIN) Drug Patent Profile

« Back to Dashboard

Which patents cover Meretek Ubt Kit (w/ Pranactin), and what generic alternatives are available?

Meretek Ubt Kit (w/ Pranactin) is a drug marketed by Otsuka America and is included in one NDA.

The generic ingredient in MERETEK UBT KIT (W/ PRANACTIN) is urea c-13. There is one drug master file entry for this compound. Additional details are available on the urea c-13 profile page.

Summary for MERETEK UBT KIT (W/ PRANACTIN)

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	51
Patent Applications:	120
DailyMed Link:	MERETEK UBT KIT (W/ PRANACTIN) at DailyMed

US Patents and Regulatory Information for MERETEK UBT KIT (W/ PRANACTIN)

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Otsuka America	MERETEK UBT KIT (W/ PRANACTIN)	urea c-13	FOR SOLUTION;ORAL	020586-001	Sep 17, 1996		DISCN	No	No

Expired US Patents for MERETEK UBT KIT (W/ PRANACTIN)

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Otsuka America	MERETEK UBT KIT (W/ PRANACTIN)	urea c-13	FOR SOLUTION;ORAL	020586-001	Sep 17, 1996
Otsuka America	MERETEK UBT KIT (W/ PRANACTIN)	urea c-13	FOR SOLUTION;ORAL	020586-001	Sep 17, 1996

Meretek UBT Kit With Pranactin: Market Dynamics, Patent Position, and Financial Trajectory

Last updated: September 30, 2026

Meretek UBT Kit with Pranactin is an FDA-approved, prescription, noninvasive diagnostic for detecting active Helicobacter pylori infection. Its commercial value comes from recurring testing demand, not from durable patent exclusivity. The product competes with stool-antigen assays, endoscopic testing, and other carbon-13 urea breath tests. Public filings do not disclose standalone Meretek revenue, profitability, market share, or product-level guidance.

What is Meretek UBT Kit with Pranactin?

Meretek UBT Kit is a carbon-13 urea breath test. The kit contains carbon-13-labeled urea, marketed under the Pranactin name, which is metabolized by H. pylori urease when the organism is present in the stomach. The resulting labeled carbon dioxide is measured in exhaled breath.

Attribute	Meretek UBT Kit with Pranactin
Product type	Prescription diagnostic kit
Active diagnostic agent	Carbon-13 urea
Target condition	Active H. pylori infection
Primary uses	Initial diagnosis and post-treatment confirmation
Administration	Oral solution followed by breath sampling
Therapeutic class	Not applicable; diagnostic product
FDA pathway	Approved drug-device diagnostic combination
Biosimilar exposure	None
Primary alternatives	Stool-antigen tests, endoscopy with biopsy, other urea breath tests

The FDA labeling emphasizes that antibiotics, bismuth, proton-pump inhibitors, and other acid-suppressive therapies can affect test accuracy. A positive result generally indicates active infection, while serology is less useful for confirming eradication because antibodies can remain after treatment.[1]

What is the FDA regulatory status of Meretek UBT Kit?

Meretek UBT Kit is an FDA-approved prescription diagnostic. Its regulatory position differs from that of a conventional pharmaceutical because the product is used to generate diagnostic information rather than to treat disease.

The product’s approval is commercially important because competitors must establish their own regulatory basis for comparable carbon-13 breath testing systems. That requirement creates a regulatory barrier, but it is weaker than an active composition-of-matter patent. Competitors can enter with alternative approved kits, analyzers, or testing workflows.

The FDA approval does not establish continuing market availability. Drug listing databases can remain associated with products that have limited distribution, changed ownership, or become commercially inactive. The commercial status of the specific Meretek-branded kit is therefore separate from its historical FDA approval.

What patents protect Meretek UBT Kit with Pranactin?

No material current patent moat is apparent from the public regulatory profile of Meretek UBT Kit. The product was developed and approved during the early expansion of carbon-13 urea breath testing, and any original patent protection would be well beyond its normal term.

Protection category	Meretek assessment
Active ingredient patent	No commercially relevant active patent identified
Carbon-13 urea composition patent	Any early patent term would generally have expired
Formulation patent	No material current protection identified
Method-of-use patent	No publicly evident enforceable exclusivity
Manufacturing patent	Possible process know-how, but no disclosed blocking position
Orange Book patent listing	No material current listing identified
Regulatory exclusivity	Any original new-drug exclusivity would have expired
Trade secrets	Potentially relevant for reagent manufacture and kit integration

The relevant economic barriers are likely manufacturing consistency, isotope supply, validation, instrument compatibility, reimbursement, distribution, and physician familiarity. Those barriers can support a niche business but do not prevent market entry in the way an unexpired patent would.

When does Meretek UBT Kit lose exclusivity?

Meretek’s meaningful regulatory and patent exclusivity has already expired. The product is a legacy diagnostic rather than a protected growth-stage pharmaceutical asset.

The likely commercial exclusivity timeline is:

Period	Event or implication
Initial FDA approval era	Carbon-13 urea breath testing entered the U.S. prescription diagnostic market
Early post-approval period	Regulatory exclusivity and any early patent rights supported market establishment
Following patent term	Competitors could develop alternative carbon-13 breath tests
Current period	Competition is governed primarily by regulatory approval, contracting, reimbursement, and distribution

A precise patent-expiration date cannot be assigned without identifying a specific issued patent tied to the marketed formulation or method. No such active blocking patent is evident in the current public record.

What is the Orange Book status of Meretek UBT Kit?

The Orange Book is relevant because Meretek is regulated through an FDA drug approval framework, but Orange Book presence does not imply active patent protection. An FDA-approved product may have no listed patents, and an old product may have regulatory history without current commercial exclusivity.

The practical Orange Book conclusion is:

1. Meretek has no apparent current patent-based entry barrier.
2. A generic or competing diagnostic does not necessarily follow the conventional ANDA model used for a tablet or capsule.
3. A competitor may need its own FDA clearance or approval, depending on the product’s claims, technology, and degree of similarity.
4. Patent litigation risk appears low relative to regulatory and commercial execution risk.

Are there Paragraph IV challenges to Meretek UBT Kit?

No prominent public Paragraph IV litigation is associated with Meretek UBT Kit. That result is commercially unsurprising. Paragraph IV litigation is most common for high-volume prescription drugs with large remaining patent estates. Meretek is an older diagnostic kit with no apparent current Orange Book patent barrier.

The more relevant competitive actions would be:

• FDA submissions for alternative carbon-13 breath tests.
• Laboratory-developed testing using validated breath-analysis platforms.
• Expansion of stool-antigen testing.
• Contracting by hospitals, gastroenterology practices, and reference laboratories.
• Price competition among kit suppliers and analyzer vendors.

What formulations and methods are protected?

The commercial product depends on more than carbon-13 urea alone. The kit may incorporate:

• A measured carbon-13 urea dose.
• A reconstitution or administration solution.
• Citric acid or another gastric-acidifying component.
• Breath-collection bags or tubes.
• Timing instructions.
• Analyzer calibration and interpretation software.
• Quality-control procedures.

Pranactin-related formulation know-how may improve test performance and user convenience. It is unlikely to create durable exclusivity unless protected by an unexpired patent, proprietary manufacturing process, or contractual distribution arrangement.

Method-of-use protection is also limited. The basic clinical applications, including diagnosis before eradication therapy and confirmation after treatment, are established uses. New claims could be commercially relevant only if they were tied to a distinct patient population, timing protocol, diagnostic threshold, or workflow that survived patent examination and litigation.

How does Meretek compare with competing H. pylori tests?

Urea breath testing is strongest when clinicians need a noninvasive measure of active infection or confirmation of eradication. Stool-antigen testing is often less expensive and easier to deploy in primary care. Endoscopy provides direct visualization and biopsy-based testing but is invasive and usually reserved for patients with alarm symptoms or another clinical indication.

Test type	Commercial strength	Main limitation
Carbon-13 urea breath test	High accuracy, noninvasive, useful for test-of-cure	Requires patient preparation and breath analyzer
Stool-antigen test	Lower infrastructure cost and broad accessibility	Sample handling and patient acceptance
Serology	Simple blood collection	Cannot reliably distinguish active from past infection
Endoscopic biopsy testing	Enables direct tissue assessment	Invasive and more expensive

The American College of Gastroenterology recommends test-of-cure evaluation after treatment using a urea breath test, fecal antigen test, or biopsy-based test, with appropriate medication washout before testing.[2] This supports recurring demand for urea breath testing but does not guarantee that Meretek captures that demand.

What market dynamics drive Meretek demand?

Demand is linked to the prevalence of H. pylori, guideline-driven testing, treatment follow-up, and healthcare access. The American College of Gastroenterology has expanded emphasis on identifying infected patients and confirming eradication after therapy.[2] Changing antibiotic resistance patterns also increase the need for post-treatment verification.

The main market drivers are:

• Increased detection of H. pylori in primary care and gastroenterology.
• Higher compliance with test-of-cure recommendations.
• Use of noninvasive testing instead of endoscopy for uncomplicated patients.
• Replacement demand for breath analyzers and collection consumables.
• Hospital and laboratory purchasing contracts.
• Coverage decisions by commercial insurers and government programs.

The main constraints are:

• Lower-cost stool-antigen competition.
• Reimbursement pressure.
• Patient preparation requirements.
• Dependence on qualified breath-analysis equipment.
• Limited public awareness of the specific Meretek brand.
• Potential substitution by other carbon-13 urea products.

What is the financial trajectory of Meretek UBT Kit?

No public company filing provides standalone revenue, gross margin, operating income, or cash flow for Meretek UBT Kit. Product-level financial analysis therefore must rely on market structure rather than reported brand results.

Meretek’s likely financial profile is a mature, niche diagnostic franchise:

Financial factor	Likely effect
Unit demand	Stable to modestly growing with testing volumes
Pricing	Vulnerable to payer and institutional contracting
Gross margin	Potentially attractive for a specialized reagent kit
Capital intensity	Moderate because of analyzer and quality-control requirements
Revenue visibility	Better where tied to recurring laboratory contracts
Growth ceiling	Limited by test substitution and product age
Patent contribution	Minimal in the current period
Strategic value	Distribution access, installed equipment, and recurring consumables

The strongest economic model for the product is recurring reagent consumption supported by an installed base of compatible analyzers. Revenue is more defensible when the supplier controls the kit, instrument, workflow, and service relationship. A stand-alone reagent without proprietary equipment has greater substitution risk.

Meridian Bioscience, historically associated with diagnostic products, reported consolidated results across multiple product lines rather than separately reporting Meretek revenue. Meridian agreed to be acquired by SD Biosensor in 2022 in a transaction valued at approximately $1.53 billion, but that transaction does not establish the value of Meretek as an individual product.[3] The absence of product-level disclosure prevents a reliable estimate of Meretek’s contribution to Meridian or its current owner.

Which companies are challenging Meretek?

Competition comes from diagnostic companies offering carbon-13 breath tests, breath analyzers, stool-antigen assays, and integrated gastroenterology testing services. Otsuka’s BreathTek UBT is a prominent branded alternative in the U.S. market. Generic-equivalent competition may also arise from regional diagnostic suppliers and laboratory-developed tests.

The competitive landscape is defined less by Paragraph IV litigation than by:

• FDA approval and labeling claims.
• Analyzer placement.
• Hospital and laboratory contracts.
• Reimbursement.
• Supply reliability for carbon-13 urea.
• Test turnaround time.
• Physician and laboratory familiarity.

What generic launch risks exist?

A conventional generic launch is unlikely to be the principal threat. The larger risk is substitution by an alternative FDA-cleared or FDA-approved diagnostic platform.

A competitor can weaken Meretek’s economics without infringing a patent by offering:

1. A lower-cost stool-antigen test.
2. A different carbon-13 urea kit.
3. A more convenient analyzer workflow.
4. Better payer coverage.
5. Higher-throughput laboratory processing.
6. A bundled gastroenterology diagnostic service.

Manufacturing risk also matters. Carbon-13-labeled urea requires isotope management, validated synthesis, quality control, packaging, and stable supply. These requirements create operational friction, but they are not equivalent to enforceable patent protection.

What litigation and settlement agreements affect Meretek?

No major current patent litigation or public settlement agreement appears to materially affect Meretek UBT Kit. The absence of litigation is consistent with an old diagnostic product that lacks a valuable, unexpired patent estate.

The principal legal risks are more likely to involve:

• FDA labeling and advertising compliance.
• Product liability.
• Reimbursement disputes.
• Supply and distribution contracts.
• Quality-system compliance.
• Diagnostic performance claims.
• Intellectual-property disputes over newer analyzers or formulations.

What is the investment outlook for Meretek?

Meretek is better characterized as a mature, cash-generating niche diagnostic than as a platform for pharmaceutical-style growth. Its value depends on continued testing volume, supply reliability, reimbursement, and commercial access.

The product has three potential strategic advantages:

• Established clinical utility.
• Recurring demand for post-treatment testing.
• Compatibility with a broader diagnostic distribution network.

Its weaknesses are equally clear:

• No apparent current patent exclusivity.
• Limited brand visibility compared with larger diagnostic platforms.
• Substitution by stool-antigen testing and competing breath tests.
• Lack of public standalone financial reporting.
• Dependence on healthcare purchasing and reimbursement.

Key Takeaways

• Meretek UBT Kit with Pranactin is a carbon-13 urea breath test for active H. pylori detection.
• Its commercial relevance is diagnostic and recurring, not therapeutic.
• No material current patent or Orange Book exclusivity is apparent.
• Paragraph IV litigation is not a meaningful present risk.
• The main competitive threats are alternative breath tests, stool-antigen assays, and laboratory-developed testing.
• Public filings do not disclose Meretek-specific revenue or profitability.
• Financial performance is likely mature and niche, with value concentrated in recurring test volume, analyzer access, distribution, and reimbursement.
• Manufacturing and regulatory know-how may support the product, but they do not appear to create a durable blocking position.

FAQs

Is Meretek UBT Kit the same as BreathTek UBT?

No. Both are carbon-13 urea breath-test products for H. pylori, but they are separate branded products and may have different sponsors, kit components, analyzers, labeling, and commercial arrangements.

Does Meretek UBT Kit have a patent-protected monopoly?

No material current patent monopoly is apparent. The product’s competitive position is more likely based on regulatory approval, distribution, manufacturing capability, and clinical adoption.

Is Meretek UBT Kit a biologic or biosimilar product?

No. It is a diagnostic drug product containing carbon-13-labeled urea. Biosimilar regulations do not apply.

Can a laboratory replace Meretek with a stool-antigen test?

Potentially. Stool-antigen tests are recognized alternatives for diagnosing active infection and confirming eradication, subject to applicable clinical guidelines, medication washout, laboratory validation, and payer requirements.

What would increase Meretek’s commercial value?

Growth in test-of-cure utilization, stronger laboratory contracting, improved analyzer integration, reliable carbon-13 urea supply, favorable reimbursement, and evidence supporting use in broader testing populations would improve its commercial position.

References

1. U.S. Food and Drug Administration. (n.d.). Meretek UBT Kit with Pranactin prescribing information. DailyMed. https://dailymed.nlm.nih.gov/

2. American College of Gastroenterology. (2024). ACG clinical guideline: Treatment of Helicobacter pylori infection. The American Journal of Gastroenterology. https://gi.org/

3. Meridian Bioscience, Inc. (2022). Meridian Bioscience announces definitive agreement to be acquired by SD Biosensor. https://ir.meridianbioscience.com/